Menu Search Icon

Search

Department of Medicine Annual Report FY 2014

Publications

Division of Hematology & Oncology:
SELECTED PUBLICATIONS

Books Edited

  1. Marcus R, Sweetenham JW, Williams ME, editors. Lymphoma: pathology, diagnosis, and treatment. 2nd ed. New York: Cambridge University Press; 2014.
  2. Dreyling M, Williams ME, editors. Rare lymphomas. Heidelberg: Springer; 2014.

Selected Publications 2013 (July – December)

  1. Aronow ME, Portell CA, Rybicki LA, Sweetenham JW, Singh AD. Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. Ophthalmology. 2013;120:1915-9. doi:10.1016/ j.ophtha.2013.02.003. Epub 2013 May 9.
  2. Bedoya-Reina OC, Ratan A, Burhans R, Kim HL, Giardine B, Riemer C, Li Q, Olson TL, Loughran TP Jr, Vonholdt BM, Perry GH, Schuster SC, Miller W. Galaxy tools to study genome diversity. Gigascience. 2013;2:17. doi: 10.1186/2047-217X-2-17.
  3. Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A, His ED. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol. 2013;163:72-80. doi: 10.1111/bjh.12498. Epub 2013 Jul 25.
  4. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688-95. doi: 10.1200/JCO.2013.49.2835. Epub 2013 Sep 3.
  5. Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagström S, Zhang D, Ellonen P, Tichelli A, Nissen C, Lichtin AE, Wodnar-Filipowicz A, Mufti GJ, List AF, Mustjoki S, Loughran TP Jr, Maciejewski JP. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453-9. doi: 10.1182/ blood-2013-04-494930. Epub 2013 Aug 7.
  6. Judge JM, Brill LB 2nd, Smith KT, Deacon DH, Patterson JW, Grosh WW, Jungbluth AA, Gnjatic S, Slingluff CL Jr. A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. Cancer Immunol Immunother. 2013;62:1327-34. doi:10.1007/ s00262-013-1433-7. Epub 2013 May 12.
  7. Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP Jr, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013;191:3578-93. doi: 10.4049/jimmunol.1203424. Epub 2013 Sep 6.
  8. Powell SF, Beitinjaneh A, Tessema M, Bliss RL, Kratzke RA, Leach J, Dudek AZ. Phase II study of topotecan and bevacizumab in advanced, refractory non-small-cell lung cancer. Clin Lung Cancer. 2013;14:495-501. doi:10.1016/j.cllc.2013.04.009. Epub 2013 Jun 28.
  9. Rahma OE, Burotto M, Do Canto LM, Germanos AA, Haddad BR, Marshall JL. Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence. World J Gastrointest Oncol. 2013;5:198-203. doi:10.4251/wjgo.v5.i11.198.
  10. Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W. The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc. 2013;61:2043-4. doi: 10.1111/jgs.12536.
  11. Ryland LK, Doshi UA, Shanmugavelandy SS, Fox TE, Aliaga C, Broeg K, Baab KT, Young M, Khan O, Haakenson JK, Jarbadan NR, Liao J, Wang HG, Feith DJ, Loughran TP Jr, Liu X, Kester M. C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. PLoS One. 2013; 8:e84648. doi: 10.1371/journal.pone.0084648. eCollection 2013.
  12. Slingluff CL Jr, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013;19:3611-20. doi: 10.1158/1078-0432.CCR-12-3919. Epub 2013 Apr 25.
  13. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.
  14. Williams ME, Bernstein SH, Jares P, Kahl BS, Witzig TE, Gordon LI. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. [Review] Leuk Lymphoma. 2013;54:1882-90. doi:10.3109/10428194.2013.771400. Epub 2013 Mar 4.
  15. Yi F, Amarasinghe B, Dang TP. Manic fringe inhibits tumor growth by suppressing Notch3 degradation in lung cancer. Am J Cancer Res. 2013;3:490-9. eCollection 2013.

Selected Publications 2014 (January – June)

  1. Aronow ME, Portell CA, Sweetenham JW, Singh AD. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology. 2014;121:334-41. doi:10.1016/ j.ophtha.2013.09.004. Epub 2013 Oct 18.
  2. Cheng J, Talamo G, Malysz J, Ochmann M, Lamy T, Loughran TP Jr. Report of 6 Cases of Large Granular Lymphocytic Leukemia and Plasma Cell Dyscrasia. Clin Lymphoma Myeloma Leuk. 2014 Jun 12. pii: S2152-2650(14)00130-X. doi: 10.1016/j.clml.2014.04.001. [Epub ahead of print]
  3. Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med. 2013 Sep 18;5(203):203ra125. doi: 10.1126/scitranslmed.3006061.
  4. Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP Jr, Wang HG. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Cancer Biol Ther. 2014 May 19;15(8). [Epub ahead of print]
  5. Fracasso PM, Goodner SA, Creekmore AN, Morgan HP, Foster DM, Hardmon AA, Engel SJ, Springer BC, Mathews KJ, Fisher EB, Walker MS. Coaching intervention as a strategy for minority recruitment to cancer clinical trials. J Oncol Pract. 2013;9:294-9. doi: 10.1200/JOP.2013.000982. Epub 2013 Oct 15.
  6. Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW, Chianese-Bullock KA, Slingluff CL Jr. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother. 2014 Apr 23. [Epub ahead of print]
  7. Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest. 2014;124:2147-59. Epub 2014 Apr 1.
  8. Myint ZW, Sen JM, Watts NL, Druzgal TJ, Nathan BR, Ward MD, Boyer JE, Fracasso PM. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2014;13:127-30. doi: 10.1016/j.clcc.2013.12.003. Epub 2013 Dec 27.
  9. Portell CA, Advani AS. Novel targeted therapies in acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55:737-48. doi:10.3109/10428194.2013.823493. Epub 2013 Aug 28.
  10. Portell CA, Aronow ME, Rybicki LA, Macklis R, Singh AD, Sweetenham JW. Clinical characteristics of 95 patients with ocular adnexal and uveal lymphoma: treatment outcomes in extranodal marginal zone subtype. Clin Lymphoma Myeloma Leuk. 2014;14:203-10. doi: 10.1016/j.clml.2013.10.011. Epub 2013 Nov 15.
  11. Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55. doi: 10.1186/1479-5876-12-55.
  12. Rajala HL, Porkka K, Maciejewski JP, Loughran TP Jr, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med. 2014;46:114-22. doi: 10.3109/07853890.2014.882105. Epub 2014 Feb 11.
  13. Ren T, Yang J, Broeg K, Liu X, Loughran TP Jr, Cheng H. Developing an in vitro model of T cell type of large granular lymphocyte leukemia. Leuk Res. 2013;37:1737-43. doi:0.1016/j.leukres.2013.10.002. Epub 2013 Oct.
  14. Steinway SN, LeBlanc F, Loughran TP Jr. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014;28:87-94. doi:10.1016/j.blre.2014.02.001. Epub 2014 Mar 7.
  15. Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol. 2013;31:4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.
  16. Zhang L, Ramchandren R, Papenhausen P, Loughran TP, Sokol L. Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. Eur J Haematol. 2014 Mar 17. doi: 10.1111/ejh.12313. [Epub ahead of print]
In This Section down-arrow
Menu